Anavex Evidence Is Copious — But Unconsidered
Well, it’s not as though one grad student 10 years ago fed a bit of Anavex 2-73 to a cage full of rats with some generalized central nervous system problem, and they all got better — providing the only known hint of useful efficacy.
Instead, there are a host of well-controlled, extensive, precise murine studies of Anavex drugs against a number of diseases. They all point to treatment efficacies.
Of course, legacy (dare I say, last-century) Alzheimer’s stakeholders continue to be locked into a focus solely on waste proteins, beta-amyloid plagues and tangles of tau proteins, as the only things to which new treatments should be directed. Clear those proteins; no Alzheimer’s.
And, that’s true. But the multitude of immunological trials Big Pharmaceuticals have spent billions of dollars on have all been profound failures. Now we see reports that a number of Big Pharmas have turned away from Alzheimer’s research.
Nonetheless, the Anavex data have been published. The Anavex sigma-1 receptor agonist molecules offer the best hope to solve the Alzheimer’s problem. They are safe, and they work.
But the Anavex evidence, whether now in murines, or soon, in humans, is going to be resisted. It negates the vaunted pronouncements of the real Alzheimer’s experts. Professional research careers are threatened. Entire floors of medical research labs will become vacant if Anavex assumes the central position and focus of Alzheimer’s research.
Frankly, one needn’t be able to describe or properly pronounce the names of the many molecules in any of the several chemical pathways in properly-functioning neurons to examine the evidence about which Alzheimer’s treatment approach is heading in the right direction. Billions of dollars of Big Pharma monies continue to prove that approach will not yield effective, safe Alzheimer’s treatments.
All of the existing data for Anavex, however, is positive and supportive. Ideally and intelligently, the Alzheimer’s stakeholders community would be pushing hard for clinical studies to get Anavex 2-73 to market. But intelligence is not the controlling factor. It’s self-gratifying protection of professional careers.
Two professions are noted, through centuries, to be exceptionally resistant to change. Farming and medicine. Both place full stock on what has been practiced previously and presently. Anything new that confronts accepted knowledge and experience is vehemently resisted.
We see that, of course, with Anavex and its unique science.
AI
